RemeGen Co., Ltd. appointed Tong Shaojing as the chief financial officer with effect from September 28, 2023. Ms. Tam Pak Yu, Vivien () (``Ms. Tam'') will continue to serve as the other joint company secretary of the Company. Mr. Tong has more than 21 years of experience in investment banking, focusing on the global healthcare sector, and has acquired a deep understanding of both the U.S. and Asian healthcare markets.

From June 2019 to December 2022, he served as the chief financial officer of InnoCare Pharma Limited (), a company listed on The Stock Exchange of Hong Kong Limited (the ``Stock Exchange'') (stock code: 9969) and the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688428). From July 2013 to May 2019, he worked at UBS AG with his last position being an executive director in the investment banking research department. From May 2008 to May 2013, he worked at Bank of America Merrill Lynch with his last position being a director in global research.

From June 2001 to April 2008, he worked as an equity analyst in multinational pharmaceutical companies equity research at Mehta Partners. Mr. Tong obtained his bachelor of science degree in material science and engineering from the University of Science and Technology of China () in the PRC in July 1993. He further obtained his master's degree in chemistry from the University of Pittsburgh in the United States in August 1996, and his master of business administration degree in finance from New York University in the United States in May 2001.